SecBot SecBot
SECBOTREPLAY Home › Report › ABCL

ABCL · CEO stake unchanged at 19.7%

AbCellera Biologics Inc. · SC 13G/A filed Nov 13, 2026 at 16:15 ET

At the news

NEUTRALIMPACT 2/10

SC 13G/A filed Nov 13, 2026 at 16:15 ET

CEO Carl Hansen filed an amended Schedule 13G/A disclosing a 19.7% beneficial ownership stake in AbCellera as of September 30, 2026, unchanged from the prior filing. The filing is a routine periodic update with no change in position.

  • Carl L.G. Hansen beneficially owns 65,913,149 common shares (19.7% of outstanding) as of September 30, 2026
  • Thermopylae Holdings Ltd., wholly owned by Hansen, directly holds 56,134,097 shares (17.2%)
  • Hansen's stake includes 898,000 shares held directly and 8,881,052 shares issuable on option exercise within 60 days
  • Stake is unchanged from the prior SC 13G/A filed May 7, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access